CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has announced its financial results for 2024, marking a ...
Citizens JMP raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $443 from $427 and keeps an Outperform rating on the shares.
Citi raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $469 from $378 and keeps a Buy rating on the shares post the Q4 ...
Madrigal Pharmaceuticals Inc (MDGL) reports robust financial performance with significant milestones in Rezdiffra's launch ...
The Business Research Company Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
Hosted on MSN17h
Eli Lilly pays $10m upfront for Organovo’s FXR agonistEli Lilly (Lilly) has agreed to make a $10m upfront payment for full worldwide rights to San Diego-based Organovo Holdings’ ...
Investing.com -- Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ: NASDAQ: MDGL) rose 17% following the announcement of their fourth-quarter and full-year 2024 financial results, which included a ...
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) reported two-year results from the open-label compensated MASH cirrhosis (F4c) ...
The British drugmaker claimed study success in a first-line setting in breast cancer. Elsewhere, Rezdiffra sales continued to ...
Madrigal Pharmaceuticals, Inc.'s Rezdiffra, the first approved drug for MASH, showed strong sales growth, with Q4 net sales ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback